Former premier Lin Chuan (林全) yesterday clarified that he would not be working to help promote government policies in his new role as chairman of TTY Biopharm Co (台灣東洋藥品).
He said that his efforts would be focused on elevating TTY Biopharm’s profile in international markets, and that success of the nation’s biotechnology sector is not dependent on any single company.
Market observers have been upbeat on Lin’s appointment to the helm of the pharmaceutical company, on expectations that he would work as a proponent of President Tsai Ing-wen’s (蔡英文) “five plus two” innovative industries plan, which includes the biotechnology sector.
As the Executive Yuan is not a regulator of industries, his appointment does not violate conflict of interest rules nor the revolving-door policy for government workers, Lin said at a news conference in Taipei.
“Not every former government worker aims to become a ‘guardian deity’ for businesses as they transition to the private sector,” Lin said.
Amid rapid consolidation among the world’s biggest pharmaceutical companies, Taiwanese biotechnology firms must be able to differentiate and distinguish themselves by specializing in a few chosen fields, he said.
Lin said that he and TTY Biopharm president Clark Hsiao (蕭英鈞) have set their sights on growing the firm’s revenue 10-fold to US$1 billion.
The company reported that sales last year rose 8.8 percent annually to NT$4.09 billion (US$138.39 million), driven by rising shipments of chemotherapy drugs from its contract manufacturing business.
Net income last year rose 7.5 percent annually to NT$1.35 billion, with earnings per share of NT$5.43, setting a new record high, the company said.
TTY Biopharm shares yesterday surged 8 percent to NT$109 before settling at NT$105.50, a 5 percent increase.
Lin’s appointment also spurred on rallies for several other biotechnology stocks during yesterday’s session, dealers said.
Zhang Yazhou was sitting in the passenger seat of her Tesla Model 3 when she said she heard her father’s panicked voice: The brakes do not work. Approaching a red light, her father swerved around two cars before plowing into a sport utility vehicle and a sedan, and crashing into a large concrete barrier. Stunned, Zhang gazed at the deflating airbag in front of her. She could never have imagined what was to come: Tesla Inc sued her for defamation for complaining publicly about the vehicles brakes — and won. A Chinese court ordered Zhang to pay more than US$23,000 in
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday said that its investment plan in Arizona is going according to schedule, following a local media report claiming that the company is planning to break ground on its third wafer fab in the US in June. In a statement, TSMC said it does not comment on market speculation, but that its investments in Arizona are proceeding well. TSMC is investing more than US$65 billion in Arizona to build three advanced wafer fabs. The first one has started production using the 4-nanometer (nm) process, while the second one would start mass production using the
A TAIWAN DEAL: TSMC is in early talks to fully operate Intel’s US semiconductor factories in a deal first raised by Trump officials, but Intel’s interest is uncertain Broadcom Inc has had informal talks with its advisers about making a bid for Intel Corp’s chip-design and marketing business, the Wall Street Journal reported, citing people familiar with the matter. Nothing has been submitted to Intel and Broadcom could decide not to pursue a deal, according to the Journal. Bloomberg News earlier reported that Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is in early talks for a controlling stake in Intel’s factories at the request of officials at US President Donald Trump’s administration, as the president looks to boost US manufacturing and maintain the country’s leadership in critical technologies. Trump officials raised the
From George Clooney to LeBron James, celebrities in the US have cashed in on tequila’s soaring popularity, but in Mexico, producers of the agave plant used to make the country’s most famous liquor are nursing a nasty hangover. Instead of bringing a long period of prosperity for farmers of the spiky succulent, the tequila boom has created a supply glut that sent agave prices slumping. Mexican tequila exports surged from 224 million liters in 2018 to a record 402 million last year, according to the Tequila Regulatory Council, which oversees qualification for the internationally recognized denomination of origin label. The US, Germany, Spain,
RSS